dc.contributor.author | Vinje, Cathrine Alvær | |
dc.contributor.author | Vigmostad, Maria Nyre | |
dc.contributor.author | Kjosavik, Svein Reidar | |
dc.contributor.author | Grönberg, Henrik | |
dc.contributor.author | Gilje, Bjørnar | |
dc.contributor.author | Skeie, Svein | |
dc.date.accessioned | 2023-10-27T12:51:20Z | |
dc.date.available | 2023-10-27T12:51:20Z | |
dc.date.created | 2023-10-22T13:08:40Z | |
dc.date.issued | 2023-10 | |
dc.identifier.citation | Vinje, C.A., Vigmostad, M.N., Kjosavik, S.R., Grönberg, H., Gilje, B. & Skeie,S. (2023) Prostate Biopsies Can Be Omitted in Most Patients with a Positive Stockholm3 Test and Negative Prostate Magnetic Resonance Imaging. European Urology Focus | en_US |
dc.identifier.issn | 2405-4569 | |
dc.identifier.uri | https://hdl.handle.net/11250/3099197 | |
dc.description.abstract | Background
Magnetic resonance imaging (MRI) combined with the Stockholm3 test can be used to inform biopsy decision-making in patients with a suspicion of prostate cancer.
Objective
To determine the consequence of omitting biopsies in men with a positive Stockholm3 test and a negative MRI.
Design, setting, and participants
In a real-life setting, 438 men with a positive Stockholm3 test and a negative MRI underwent systematic biopsies from 2017 to 2020.
Outcome measurements and statistical analysis
The Stockholm3 test result is a percentage risk score with or without a prostate volume cutoff. The main outcomes were the number of clinically significant (Gleason grade group [GG] ≥2) and nonsignificant (GG 1) prostate cancers.
Results and limitations
Median prostate-specific antigen was 4.5 ng/ml (interquartile range 2.8–6.4 ng/ml) and the median age was 69 yr. Systematic biopsies detected grade group (GG) ≥2 disease in 48 men (11%, 95% confidence interval [CI] 8.4–14.2%) and GG 1 disease in 94 men (21.5%, 95% CI 17.9–25.6%). Of 256 patients without a volume cutoff in the test report, GG ≥2 was detected in 37 men (14.5%, 95% CI 10.7–19.3%). Omitting biopsies in patients with a volume cutoff would miss 11 GG ≥2 cases (6%, 95% CI 3.4–10.5%), reduce the number of GG 1 cases detected by 37 (39.4%, 95% CI 30.1–49.5%), and avoid a total of 182 biopsies (41.6%, 95% CI 37.0–46.2%). Limitations include the lack of follow-up data.
Conclusions
Systematic biopsies can be omitted in patients with a positive Stockholm3 test and a negative MRI when there is a volume cutoff in the test report. With no volume cutoff, biopsies can be considered with shared decision-making.
Patient summary
When investigated on suspicion of prostate cancer with a positive Stockholm3 test and a negative MRI (magnetic resonance imaging), prostate biopsies are only necessary for a subgroup of patients. This can spare some men from undergoing biopsies and reduce the detection of clinically insignificant cancers. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier B.V. on behalf of European Association of Urology | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.subject | Stockholm3 test | en_US |
dc.subject | urologi | en_US |
dc.subject | prostatakreft | en_US |
dc.title | Prostate Biopsies Can Be Omitted in Most Patients with a Positive Stockholm3 Test and Negative Prostate Magnetic Resonance Imaging | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | © 2023 The Author(s). | en_US |
dc.subject.nsi | VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Nefrologi, urologi: 772 | en_US |
dc.subject.nsi | VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762 | en_US |
dc.source.pagenumber | 6 | en_US |
dc.source.journal | European Urology Focus | en_US |
dc.identifier.doi | 10.1016/j.euf.2023.08.009 | |
dc.identifier.cristin | 2187332 | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |